A rapid and simple HPTLC assay for therapeutic drug monitoring of capecitabine in colorectal cancer patients

2017 ◽  
Vol 32 (2) ◽  
pp. e4100 ◽  
Author(s):  
Sonali G. Thorat ◽  
Rupesh V. Chikhale ◽  
Madhukar R. Tajne
Keyword(s):  
Colorectal Cancer ◽  
Therapeutic Drug Monitoring ◽  
Cancer Patients ◽  
Drug Monitoring ◽  
Therapeutic Drug ◽  
Colorectal Cancer Patients

Development and Validation of HPLC and HPTLC Methods for Therapeutic Drug Monitoring of Capecitabine in Colorectal Cancer Patients

2019 ◽  
Vol 57 (10) ◽  
pp. 892-900
Author(s):  
Sonali G Thorat ◽  
Rupesh V Chikhale ◽  
Madhukar R Tajne
Keyword(s):  
Colorectal Cancer ◽  
Therapeutic Drug Monitoring ◽  
Combination Therapy ◽  
Drug Monitoring ◽  
High Performance ◽  
Internal Standard ◽  
Therapeutic Drug ◽  
Chemotherapy Agent ◽  
Assay Methods ◽  
Colorectal Cancer Patients

Abstract Capecitabine is a prodrug of 5-fluorouracil, employed as a monotherapy or combination chemotherapy agent for treatment of colorectal cancer. Combination therapy of capecitabine consists of oxaliplatin, and hence, it becomes essential to determine that co-administration does not affect its metabolism. High-performance liquid chromatography and high-performance thin-layer chromatography methods were developed and validated to determine the plasma concentration of capecitabine. In this study, blood samples from 12 patients with colorectal cancer were collected and analyzed by both methods with a reference internal standard. Two groups consisting of six patients each were formed: the first group was treated with capecitabine monotherapy, the second group with capecitabine + oxaliplatin combination therapy. The results of analysis from both the methods indicated that there is no significant drug–drug interaction. The co-administration of oxaliplatin did not affect the metabolism of capecitabine. Both assay methods were compared for their sensitivity, robustness and specificity. It was found that both the assay methods were suitable for therapeutic drug monitoring of capecitabine.

Importance of voriconazole therapeutic drug monitoring in pediatric cancer patients with invasive aspergillosis

2012 ◽  
Vol 60 (1) ◽  
pp. 82-87 ◽  
Author(s):  
Soo-Han Choi ◽  
Soo-Youn Lee ◽  
Ji-Young Hwang ◽  
Soo Hyun Lee ◽  
Keon Hee Yoo ◽  
...  
Keyword(s):  
Therapeutic Drug Monitoring ◽  
Invasive Aspergillosis ◽  
Cancer Patients ◽  
Pediatric Cancer ◽  
Drug Monitoring ◽  
Therapeutic Drug ◽  
Pediatric Cancer Patients

scholarly journals Metastatic colorectal cancer and severe hypocalcemia following irinotecan administration in a patient with X-linked agammaglobulinemia: a case report

2019 ◽  
Vol 20 (1) ◽  
Author(s):  
Mingming Li ◽  
Wei Chen ◽  
Xiaomeng Sun ◽  
Zhipeng Wang ◽  
Xun Zou ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Therapeutic Drug Monitoring ◽  
Exome Sequencing ◽  
Whole Exome Sequencing ◽  
Drug Monitoring ◽  
Treatment Cycle ◽  
Germline Mutations ◽  
Therapeutic Drug ◽  
Immune Disorder ◽  
Whole Exome

Abstract Background X-linked agammaglobulinemia (XLA) is a primary immunodeficiency disorder caused by germline mutations in the Bruton tyrosine kinase (BTK) gene on X chromosome. These mutations disturb B-cell development, decrease immunoglobulin levels, increase susceptibility to infection or neoplasms, and increase the risk of developing colorectal cancer (CRC). For occasional cases of CRC have been reported in XLA patients, low levels of B lymphocytes and immunoglobulins induced by congenital immune disorder make them more susceptible to drug-related toxicities (DRT). Therefore, gene sequencing, therapeutic drug monitoring and any possible measurement to predict DRT should be considered before determining the course of chemotherapy for XLA patients with CRC. Case presentation In this study, we reported a 21-year-old male who developed metastatic CRC in the context of XLA. Since the whole exome sequencing and therapeutic drug monitoring did not reveal any predictive markers of DRT, we applied standard first-line chemotherapy to the patient. However, progressive disease occurred after the fifth treatment cycle. Therefore, the administration of oxaliplatin was changed to irinotecan as second-line therapy. After that, the patient firstly suffered from severe hypocalcemia and eventually died due to metastatic CRC after the eighth treatment cycle. The overall survival time was 7.5 months. Conclusions This study reported the first written record of a Chinese XLA patient with metastatic CRC and severe hypocalcemia. Whole exome sequencing and bioinformatic analysis indicated the somatic mutations in ABCA6, C6 and PAX3 genes might contribute to the early-onset and metastasis CRC. Besides, a number of germline mutations in genes related to calcium metabolism (CACNA2D4, CD36, etc.) and the administration of irinotecan were speculated to be the causes of severe hypocalcemia. We therefore suggested that in order to avoid severe DRT, clinicians should take genetic background and therapeutic drug monitoring into consideration while planning chemotherapy treatment for XLA patients with CRC.

scholarly journals Vincristine dosing, drug exposure and therapeutic drug monitoring in neonate and infant cancer patients

2021 ◽  
Author(s):  
Shelby Barnett ◽  
Farina Hellmann ◽  
Elizabeth Parke ◽  
Guy Makin ◽  
Deborah A. Tweddle ◽  
...  
Keyword(s):  
Therapeutic Drug Monitoring ◽  
Cancer Patients ◽  
Drug Monitoring ◽  
Drug Exposure ◽  
Therapeutic Drug
Sign in / Sign up

Export Citation Format

Share Document